fbpx

Alzheimer’s Disease Models

Home › CRISPR Model Creation › Neurodegenerative Diseases Models › Alzheimer’s Disease Models

Alzheimer's disease-relevant strains that are sequence validated

Alzheimer’s disease is one of the most economically and socially impactful diseases of our time. Through basic and clinical research, top genes that are mutated in Alzheimer’s disease have been identified.

However, it is complex and challenging to select the right mutants to study due to too many choices of strains and alleles (genetic models). In addition, researchers sometimes have doubts that a strain obtained from another source has not lost the mutation or undergone genetic drift.

 

Model Options

Our goal is to create a curated, reliable library of strains that are relevant to Alzheimer’s disease.  We have carefully selected:

These sequence validated strains enable researchers to:

STRAIN

HUMAN GENE

WORM GENE HOMOLOGUE

TYPE OF TRANSGENIC

PROTEIN ACTIVITY

WORM PHENOTYPE

Key Advantages of the Alzheimer’s Disease Models

Fig 1. Day-2 ALZ PSEN1 Knock-out live C. elegans on NGM plate.

This worm was dyed with both RediStain™ WormDyes  Lyso (magenta) and Neuro Green (cyan) to stain sensory neurons and apoptotic corpses in the gonad respectively.

The sel-12(ty11) mutation produces defects in vulva and neuronal development leading to a dysfunctional uterine-vulval connection and ultimately the inability to lay eggs. The worm is positioned head-down on the left and head-up on the right.

Video: Day-1 adult ALZ Humanized MAPT C. elegans in 5HT 10mM.

This worm immobilized into a ScreenChip Channel expresses GFP in the pharyngeal muscles under the control of the myo-2 promoter.

Publications (ZebrafiSh model)

Pu YZ, Liang L, Fu AL, et al. Curr Alzheimer Res. 2017;14(6):668‐679.
Koehler D, Williams FE. Neural Regen Res. 2018;13(9):1538‐1541.

Publications (C. elegans model)

Kumar DK, Choi SH, Washicosky KJ, et al. Sci Transl Med. 2016;8(340):340ra72.
Fang EF, Hou Y, Palikaras K, et al. Nat Neurosci. 2019;22(3):401‐412.
 Griffin EF, Caldwell KA, Caldwell GA. ACS Chem Neurosci. 2017;8(12):2596‐2606.

References

Levitan D et al.  Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14940-4.
McColl G et al. Mol Neurodegener. 2012 Nov 21;7:57.
Kraemer BC et al. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9980-5. Epub 2003 Jul 18.

ready to get started?

Ready to connect with us to learn more about working with our company or our technology?

Submit your inquiry below & we will get back to you soon.